Melissa O'Connor, PhD, MBA, RN, FGSA, FAAN, endowed professor in Community and Home Health Nursing, M. Louise Fitzpatrick School of Nursing, Villanova University, and director, Gerontology Interest Group, addressed gaps in research for home health care and progress toward the development of a discharge decision support tool for clinicians.
More funding and research leveraging real-world data is required to create a standardized discharge decision support tool in home health, said Melissa O'Connor, PhD, MBA, RN, FGSA, FAAN, endowed professor in Community and Home Health Nursing, M. Louise Fitzpatrick School of Nursing, Villanova University, and director, Gerontology Interest Group.
Transcript
Why is there no national standard or tool to determine when older adults are ready to be without skilled home support?
So, I'm working very hard on that. There is limited research in home health, due primarily to funding. And rigorous research takes time, as well as funding. Developing decision support in home health that is based on the evidence, and that is using real-world data is what I'm currently working on.
It's funded by a [University of California, Davis] Betty Irene Moore [School Of Nursing] fellowship for nurse leaders and innovators. But without decision support, the home health team is relying on individual clinician judgment to determine when patients are ready or when payers say they are ready rather than objective, available in real time data that will lead to the best patient outcomes.
We need to be able to identify patients who are ready for discharge vs those who are not because we don't want to just continue on with home health for everyone—we can't afford that and that doesn't make sense. But to answer your question, it's really because these things take time, they take funding, and we're working on it. So, hopefully within the next year or two, you will start to see a discharge decision support tool emerge that hopefully will be implemented nationally and embedded in the electronic health record.
Unmet Needs Remain in Secondary AML Following Treatment With HMAs
January 18th 2025The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Read More
Increased Interest in Advance Provision and Over-the-Counter Medication Abortion
January 16th 2025An increased public interest and support for medication abortion following the federal Supreme Court ruling, particularly among marginalized groups, suggests a shift towards more accessible and autonomous models of abortion care.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen